ralom, I am curious, you say ‘I knew this company inside...

ralom, I am curious, you say ‘I knew this company inside out?

Admedus specifically or any type of bio-health company?, any speccy actually, most times we will only know ‘what’ the company wishes to tell us!, hard to believe a outsider can have specific insider info.

Research seemingly often based on company spiel!, I have come to realise that a understanding of the following can be beneficial; awareness of lengthy time frames, huge costs involved in R&D and thus the necessity for CRs, that the probability of success low, that seemingly successful IP needs to be successfully commercialised in a very timely manner, against the might of incumbent market giants.

Note if BOD believe in company (significant holders) and if the share registery has at least one cornerstone investor who will regularly support that company’s CRs as it grows.

In the interim hype built up by both mangerment and traders, traders come and go, steadfast mum and dad holders remaining holders.

Timing probably very important, imo, better in at 4 cents rather than $1.80 (and ‘averaging’ down) OR in and out till the company has turned the corner.

Eg; I watch closely a stock that starts with B and is at $1 (if consolidated) posters there, imo, largely seem to have no inkling of what I said in para 3, imo, as I did very early on with Allied Health/Admedus.

On a side note; I wonder if Admedus can re-borrow till the two relevant deals in the pipeline are successfully finalised, that with borrowing combined with increasing revenue with reduced cash burn will give the company some respite.